or Try an Advanced Search...

    Technical Analysis for SPRY - ARS Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    C 8.73 2.59% 0.22
    SPRY closed up 2.59 percent on Monday, July 1, 2024, on 1.2 times normal volume. It ran into resistance at its 50 day moving average.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Flat Up
    Historical SPRY trend table...
    Date Alert Name Type % Chg
    50 DMA Resistance Bearish 0.00%
    Crossed Above 20 DMA Bullish 0.00%
    MACD Bullish Signal Line Cross Bullish 0.00%
    20 DMA Resistance Bearish 2.59%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.59%
    Pocket Pivot Bullish Swing Setup 2.59%
    Volume Surge Other 2.59%
    Gapped Up Strength 2.59%
    NR7 Range Contraction 8.45%
    Lower Bollinger Band Walk Weakness 8.04%
    Older End-of-Day Signals for SPRY ...

       Recent Intraday Alerts

    Alert Time
    20 DMA Support about 10 hours ago
    20 DMA Resistance about 10 hours ago
    50 DMA Resistance about 10 hours ago
    Up 3% about 10 hours ago
    Rose Above Previous Day's High about 10 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    SPRY Chart by TradingView
    Basic chart:

    Profile

    ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Allergy Respiratory Therapy Respiratory Diseases Type I Hypersensitivity Allergology Nasal Administration Anaphylaxis

    Is SPRY a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 28 ARS Pharmaceuticals nasal spray for anaphylaxis endorsed in EU
    Jun 28 ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
    Jun 26 US Growth Companies With High Insider Ownership To Watch
    Jun 25 ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles
    Jun 24 Owning 30% shares,institutional owners seem interested in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY),
    May 28 Top US Growth Companies With High Insider Ownership To Watch In May 2024
    May 13 ARS Pharmaceuticals Inc (SPRY) Q1 2024 Earnings: Aligns with EPS Projections Amidst Regulatory ...
    May 11 ARS Pharmaceuticals First Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.16 loss in 1Q 2023)
    May 9 ARS Pharmaceuticals GAAP EPS of -$0.11
    May 9 ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
    See more SPRY news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 11.27
    52 Week Low 2.55
    Average Volume 527,172
    200-Day Moving Average 6.78
    50-Day Moving Average 8.75
    20-Day Moving Average 8.56
    10-Day Moving Average 8.17
    Average True Range 0.44
    RSI (14) 52.83
    ADX 14.08
    +DI 24.48
    -DI 23.76
    Chandelier Exit (Long, 3 ATRs) 8.06
    Chandelier Exit (Short, 3 ATRs) 8.86
    Upper Bollinger Bands 9.48
    Lower Bollinger Band 7.64
    Percent B (%b) 0.59
    BandWidth 21.49
    MACD Line -0.17
    MACD Signal Line -0.19
    MACD Histogram 0.0174
    Fundamentals Value
    Market Cap 838.06 Million
    Num Shares 96 Million
    EPS -0.64
    Price-to-Earnings (P/E) Ratio -13.64
    Price-to-Sales 22655.34
    Price-to-Book 2.63
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 9.45
    Resistance 3 (R3) 9.40 9.12 9.33
    Resistance 2 (R2) 9.12 8.93 9.14 9.29
    Resistance 1 (R1) 8.92 8.82 9.02 8.97 9.25
    Pivot Point 8.64 8.64 8.69 8.66 8.64
    Support 1 (S1) 8.44 8.45 8.54 8.49 8.21
    Support 2 (S2) 8.16 8.34 8.18 8.17
    Support 3 (S3) 7.96 8.16 8.13
    Support 4 (S4) 8.01